Status:
UNKNOWN
Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment
Lead Sponsor:
UMC Utrecht
Collaborating Sponsors:
Sanofi
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18+ years
Brief Summary
Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the Bioday Registry.
Eligibility Criteria
Inclusion
- Adult patients with atopic dermatitis indicated for dupilumab, without current use of oral immunosuppressive treatment .
Exclusion
- Treatment with oral or ocular immunosuppressive drugs 2 weeks prior to start of dupilumab treatment
Key Trial Info
Start Date :
February 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04276623
Start Date
February 25 2020
End Date
December 31 2023
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Utrecht
Utrecht, Netherlands, 3584CX